Halozyme Therapeutics (HALO) Stock Price, News & Analysis

Company Overview

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix. This mechanism facilitates the dispersion and absorption of co-administered therapeutic agents, allowing high-volume subcutaneous injections that were previously limited to intravenous infusion. ENHANZE has been incorporated into multiple commercial partnerships, enabling pharmaceutical and biotechnology companies to develop subcutaneous formulations of existing and novel therapies.

In addition to its commercial collaborations, Halozyme maintains a pipeline of investigational products that leverage its enzyme technology. The company conducts research in oncology, immunology and inflammatory diseases, exploring novel combinations and applications of rHuPH20. Halozyme’s business model combines royalty revenues from established partner products with internal development programs to drive long-term growth and innovation.

Halozyme operates on a global scale, with collaborations spanning North America, Europe and Asia Pacific. The executive leadership team, led by President and Chief Executive Officer Helen I. Torley, brings extensive experience in biopharmaceutical development, regulatory affairs and commercial strategy. Through its technology platforms and strategic alliances, Halozyme continues to advance subcutaneous delivery solutions aimed at enhancing the patient experience and expanding therapeutic possibilities.

Key Stats

• Today's Range: $77.05 to $79.31
• 50-Day Range: $55.92 to $78.28
• 52-Week Range: $42.01 to $79.31
• Volume: 1.62 million shs
• Average Volume: 1.97 million shs
• Market Capitalization: $9.16 billion
• P/E Ratio: 17.91
• Dividend Yield: N/A
• Price Target: $68.22
• Consensus Rating: Hold

Halozyme Therapeutics Stock Analysis - MarketRank™

Halozyme Therapeutics scored higher than 91% of companies evaluated by MarketBeat, and ranked 94th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Halozyme Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 4 buy ratings, 5 hold ratings, and 2 sell ratings.

Downside Risk

Halozyme Therapeutics has a consensus price target of $68.22, representing about 12.8% downside from its current price of $78.28.

Amount of Analyst Coverage

Halozyme Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 31.50%

Earnings Growth

Earnings for Halozyme Therapeutics are expected to grow by 31.50% in the coming year, from $4.73 to $6.22 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Halozyme Therapeutics is 17.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 297.56.

Price to Earnings Ratio vs. Sector

The P/E ratio of Halozyme Therapeutics is 17.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 348.89.

Price to Earnings Growth Ratio

Halozyme Therapeutics has a PEG Ratio of 0.43. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Halozyme Therapeutics has a P/B Ratio of 27.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.27% of the float of Halozyme Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Halozyme Therapeutics has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Halozyme Therapeutics has recently increased by 12.39%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Halozyme Therapeutics does not currently pay a dividend.

Dividend Growth

Halozyme Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.12

Percentage of Shares Shorted

10.27% of the float of Halozyme Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Halozyme Therapeutics has a short interest ratio ("days to cover") of 5.5.

Change versus previous month

Short interest in Halozyme Therapeutics has recently increased by 12.39%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.19

News Sentiment

Halozyme Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 20 news articles for Halozyme Therapeutics this week, compared to 14 articles on an average week.

Search Interest

19 people have searched for HALO on MarketBeat in the last 30 days. This is an increase of 46% compared to the previous 30 days.

MarketBeat Follows

6 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,771,120.00 in company stock.

Percentage Held by Insiders

Only 2.90% of the stock of Halozyme Therapeutics is held by insiders.

Percentage Held by Institutions

97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HALO Stock Analysis - Frequently Asked Questions

How have HALO shares performed this year?

Halozyme Therapeutics' stock was trading at $47.81 at the beginning of the year. Since then, HALO stock has increased by 63.7% and is now trading at $78.28.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its quarterly earnings data on Tuesday, August, 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics's quarterly revenue was up 40.8% compared to the same quarter last year.
Read the conference call transcript.

Does Halozyme Therapeutics have any subsidiaries?

The following companies are subsidiaries of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.

Who are Halozyme Therapeutics' major shareholders?

Top institutional investors of Halozyme Therapeutics include DLD Asset Management LP (10.14%), Arrowstreet Capital Limited Partnership (2.06%), Alliancebernstein L.P. (1.99%) and Geode Capital Management LLC (1.97%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Bernadette Connaughton, Jeffrey William Henderson, Nicole Labrosse and James M Daly.
View institutional ownership trends.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 9/22/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:HALO
• CIK: 1159036
• Web: www.halozyme.com
• Phone: 858-794-8889
• Fax: 858-704-8311
• Employees: 390
• Year Founded: 1998

Price Target and Rating

• Average Price Target for Halozyme Therapeutics: $68.22
• High Price Target: $91.00
• Low Price Target: $47.00
• Potential Upside/Downside: -12.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $4.37
• Trailing P/E Ratio: 17.91
• Forward P/E Ratio: 16.53
• P/E Growth: 0.43
• Net Income: $444.09 million
• Net Margins: 47.28%
• Pretax Margin: 58.72%
• Return on Equity: 150.85%
• Return on Assets: 29.19%

Debt

• Debt-to-Equity Ratio: 4.54
• Current Ratio: 8.36
• Quick Ratio: 7.01

Sales & Book Value

• Annual Sales: $1.02 billion
• Price / Sales: 9.01
• Cash Flow: $4.67 per share
• Price / Cash Flow: 16.73
• Book Value: $2.86 per share
• Price / Book: 27.34

Miscellaneous

• Outstanding Shares: 116,970,000
• Free Float: 113,574,000
• Market Cap: $9.15 billion
• Optionable: Optionable
• Beta: 1.19